Full-Time

Director – Software Development Engineer

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Engineering Management (2)
,
Required Skills
LLM
MLOps
NoSQL
SQL
AWS
LangChain
DevOps
Requirements
  • 18 to 23 years of experience in full stack software engineering, cloud computing with a robust blend of technical expertise, strategic thinking and leadership abilities focusing on software development.
  • Demonstrated experience in managing large-scale technology projects and teams with a track record of delivering innovative and impactful solutions.
  • Hands on experience with latest framework and libraries, such as LangChain, llamaindex, Agentic framework, vectorDB, LLM, Experienced with CICD DevOps/MLOps.
  • Hands on experience with cloud computing services, such as AWS Lambda, container technology, SQL, NoSQL databases, API Gateway, SageMaker, Bedrock, etc.
Responsibilities
  • Develop strategic vision for software platform services in alignment with the company’s overall strategy.
  • Provide support to the Amgen Technology Executive Leadership and oversee the development of a Community of Practice for software Platforms.
  • Foster a culture of innovation, identify and implement software solutions that drive value to our stakeholders
  • Ensure the adoption of best practices and latest advancements in technologies across functions and business.
  • Drive the design, development and deployment of scalable software platforms and reusable accelerators that enable and increase the value of application and product teams across the enterprise.
  • Ensure the security, reliability of software platforms and seamless integration with existing systems.
  • Drive the software platform capabilities implementation, ensuring timely delivery within scope and budget.
  • Collaborate with cross functional teams to understand demand and develop solutions to meet business needs.
  • Develop and enforce governance frameworks to manage the usage and adoption of software platforms.
  • Lead and mentor a team of Engineers and Architects and foster a culture of continuous development and learning.
  • Monitor team performance and present updates to executive leadership and key stakeholders.
Desired Qualifications
  • Cloud Platform certification (AWS, Azure, GCP), specialized in solution architect, DevOps
  • Platform certification (AWS, Azure, GCP, Databricks)
  • Proficient in Python, JavaScript, SQL; Hands on experience with full stack software development, NoSQL database, docker container, container orchestration system, automated testing, and CICD DevOps
  • Build a high performing team of software development experts, foster a culture of innovation, and ensure employee growth and satisfaction to drive long-term organizational success
  • Stay updated with the latest industry trends and advancements in software technology, provide strategic leadership, and explore new opportunities for innovation
  • Be an interdisciplinary team leader who is innovative, accountable, reliable, and able to thrive in a constantly evolving environment
  • Facilitate technical discussions and decision-making processes within the team
  • Exceptional communication and people skills to effectively manage stakeholder relationships and build new partnerships.
  • Excellent verbal and written communication skills/writing skills; active listening skills; attention to detail. Strong process/business writing skills.
  • Experience in people management and passion for mentorship, culture and fostering the development of talent.
  • Ability to translate business and stakeholder feedback into accurate and efficient processes using clear language and format.
  • Strong analytic/critical-thinking and decision-making abilities.
  • Must be flexible and able to manage multiple activities and priorities with minimal direction in a rapidly changing and demanding environment.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.